Article Text

Download PDFPDF

PO.8.176 Inflammation in blood and placenta in SLE pregnancies
  1. M Stockfelt1,
  2. A Torell1,
  3. G Larsson1,
  4. H Puttonen2,
  5. D Leonard3,
  6. L Rönnblom3,
  7. M Saleh4,
  8. C Sjöwall4,
  9. H Strevens5,
  10. J Andreas6,
  11. AA Bengtsson6,
  12. E Trysberg1,
  13. M Majcuk Sennström7,
  14. A Zickert8,
  15. E Svenungsson8,
  16. I Gunnarsson8,
  17. K Christenson9,
  18. J Bylund9,
  19. B Jacobsson10,
  20. A Rudin1 and
  21. A Lundell1
  1. 1Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg ~ Sweden
  2. 2Department of Pathology, Sahlgrenska University Hospital ~ Gothenburg ~ Sweden
  3. 3Department of Medical Sciences, Rheumatology, Uppsala University ~ Uppsala ~ Sweden
  4. 4Division of Inflammation and Infection, Department of Biomedical and Clinical Sciences, Linköping University ~ Linköping ~ Sweden
  5. 5Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Skåne University Hospital ~ Lund ~ Sweden
  6. 6Department of Clinical Sciences, Rheumatology, Lund University ~ Lund ~ Sweden
  7. 7Department of Womens and Childrens Health, Division for Obstetrics and Gynecology, Karolinska University Hospital, Karolinska Institute ~ Stockholm ~ Sweden
  8. 8Karolinska Division of Rheumatology, Department of Medicine, Karolinska Institute, Karolinska University Hospital ~ Stockholm ~ Sweden
  9. 9Department of Oral Microbiology and Immunology, Institute of Odontology, Sahlgrenska Academy at the University of Gothenburg ~ Sweden
  10. 10Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg ~ Sweden


Background Adverse pregnancy outcomes, including preterm birth and preeclampsia, are more prevalent in women with SLE compared to healthy women. The immunopathological mechanisms causing these complications are largely unknown and we need methods to predict which women who are at high risk of developing them. Granulocytes are drivers of acute inflammation and have emerged as key effector cells in SLE pathogenesis. In SLE, granulocytes are activated by autoantibodies and immune complexes and granulocyte activation, identified by low CD62L expression, is associated with vascular inflammation. A particular subset of neutrophils referred to as low-density granulocytes (LDGs) was first identified in SLE and display proinflammatory characteristics compared to normal-density granulocytes (NDGs). Granulocyte activation and LDGs have not previously been studied in SLE pregnancies.

Purpose To determine whether pregnant women with SLE have increased granulocyte activation and higher proportions of LDGs in blood compared to healthy pregnant women.

Methods In this multicenter study, 44 pregnant women with SLE were included in collaboration with five Rheumatology clinics in Sweden and 20 healthy pregnant women were included at one antenatal clinic after informed consent. Clinical data related to the SLE disease and pregnancy outcome were collected. Peripheral blood samples from women with SLE and healthy women were collected in the first, second and third trimester. After density centrifugation, the proportion of LDGs among mononuclear cells and CD62L expression on LDGs and NDGs were determined by flow cytometry. Placentas were examined by one placental pathologist, blinded to the patient background.

Results The proportion of LDGs was significantly higher in all three trimesters in SLE compared to healthy pregnancies (p=0.001, p=0.02 and p=0.003, respectively). Both LDGs and NDGs from women with SLE displayed decreased surface density of CD62L compared to healthy women indicating increased activation (LDGs first trimester p=0.02, NDGs first trimester p=0.004 and third trimester p=0.02). In addition, LDGs were significantly more activated compared to NDGs in both pregnant women with SLE and healthy pregnant women. Histologic chorioamnionitis, defined by infiltration of granulocytes in the fetal membranes chorion and amnion, was present in 28% of placentas from women with SLE and in 18% of placentas from healthy women. The frequency of adverse pregnancy outcomes, including preeclampsia, miscarriage, preterm delivery, small for gestational age infant and low birth weight, was 43% among women with SLE compared to 20% among healthy women.

Conclusions We report increased granulocyte activation and inflammation in SLE compared to healthy pregnancies. Granulocyte activation may contribute to placental vascular inflammation and dysfunction, which could lead to decreased placental function in women with SLE. Prospective studies in a larger cohort including collection of postpartum blood samples are ongoing to determine whether granulocyte inflammation in blood and placenta can predict adverse pregnancy outcomes in women with SLE.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.